Nuclear FABP7 in Glioblastoma and Its Link to Poor Prognosis
Author Information
Author(s): Liang Yu, Andrew W. Bollen, Ken D. Aldape, Nalin Gupta
Primary Institution: University of California, San Francisco
Hypothesis
Increased expression of FABP7 is associated with reduced survival in glioblastoma patients.
Conclusion
Nuclear FABP7 immunoreactivity is linked to poor prognosis in glioblastoma, especially in patients with EGFR overexpression.
Supporting Evidence
- Nuclear FABP7 was associated with EGFR overexpression in glioblastoma.
- Patients with nuclear FABP7-positive tumors had shorter survival.
- FABP7 expression was analyzed in multiple glioma specimens.
Takeaway
This study found that a protein called FABP7 in the nucleus of brain tumor cells can mean the tumor is more aggressive and patients may not live as long.
Methodology
The study used immunohistochemistry to analyze FABP7 expression in glioma specimens and correlated it with clinical outcomes.
Potential Biases
Potential bias in patient selection and the retrospective nature of the study.
Limitations
The study's sample size was limited, and the findings may not apply to all glioma types.
Participant Demographics
Patients with glioblastoma, including a range of ages.
Statistical Information
P-Value
0.008
Confidence Interval
95% CI 1.05–1.888
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website